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Ullrich syndrome is a recessive congenital muscular dystrophy
affecting connective tissue and muscle. The molecular basis is
unknown. Reverse transcription–PCR amplification performed on
RNA extracted from fibroblasts or muscle of three Ullrich patients
followed by heteroduplex analysis displayed heteroduplexes in
one of the three genes coding for collagen type VI (COL6). In
patient A, we detected a homozygous insertion of a C leading to
a premature termination codon in the triple-helical domain of
COL6A2 mRNA. Both healthy consanguineous parents were carri-
ers. In patient B, we found a deletion of 28 nucleotides because of
an A 3 G substitution at nucleotide 22 of intron 17 causing the
activation of a cryptic acceptor site inside exon 18. The second
mutation was an exon skipping because of a G3 A substitution at
nucleotide 21 of intron 23. Both mutations are present in an
affected brother. The first mutation is also present in the healthy
mother, whereas the second mutation is carried by their healthy
father. In patient C, we found only one mutation so far—the same
deletion of 28 nucleotides found in patient B. In this case, it was a
de novo mutation, as it is absent in her parents. mRNA and protein
analysis of patient B showed very low amounts of COL6A2 mRNA
and of COL6. A near total absence of COL6 was demonstrated by
immunofluorescence in fibroblasts and muscle. Our results dem-
onstrate that Ullrich syndrome is caused by recessive mutations
leading to a severe reduction of COL6.
Congenital muscular dystrophy (CMD) identifies a heteroge-neous group of disorders characterized by muscle weakness
and hypotonia at birth, with a muscle pathology reminiscent of
muscular dystrophy. This heterogeneous condition varies ac-
cording to severity, associated symptoms, and outcomes (1).
Some genes have already been associated with CMDs, as, for
example, integrin receptor a7, fukitin, and the extracellular
matrix protein merosin (laminin a2) (2).
In 1930, Ullrich described two unrelated patients with CMD,
and the disorder was defined as scleroatonic muscular dystrophy.
The peculiar clinical manifestations were proximal joint con-
tractures, striking distal hyperextensibility, and normal intelli-
gence (3, 4). Since then, more than 20 patients with similar
clinical manifestations have been reported worldwide (1), and
thus recognized as a distinct form of CMD (Online Mendelian
Inheritance in Man database no. 254090). Some familial cases
show more than one sibling affected and a high incidence of
consanguinity among unaffected parents, suggesting an autoso-
mal recessive inheritance (5). Most of the patients die of
respiratory failure in the first decade of life. Merosin status is
reported as normal in Ullrich CMD (UCMD; ref. 6).
Bethlem myopathy (BM) is transmitted as an autosomal
dominant disorder and is associated with mutations in collagen
VI (COL6) genes (7, 8). This myopathy was considered as a mild
neuromuscular disorder with prominent and multiple joint f lex-
ion contractures and slowly progressive proximal muscle weak-
ness. Joint contractures mainly affect neck, elbows, knees (9),
and interphalangeal joints and may have a neonatal onset (10).
Recent clinical observations have shown that BM is a progressive
disorder in adulthood (10). A large number of patients with BM
need a wheelchair after the age of 50 years (9), and some die of
respiratory failure caused by diaphragmatic paralysis (11).
COL6 is a ubiquitous extracellular matrix protein constituted
by three chains, a1, a2, and a3, that form a monomer made up
of two globular domains linked by a relatively short triple-helix
structure that consists of Gly-Xaa-Yaa amino acid repeat se-
quences (12). The monomers assemble into dimers and then into
tetramers, which associate in an end-to-end fashion to form the
final microfilament network. The chains are encoded by
COL6A1, COL6A2, and COL6A3 genes. COL6A1 and
COL6A2 on chromosome 21q22.3 and COL6A3 on chromo-
some 2q37 were found to be linked to BM in 1996 (13, 14).
Eight mutations have been characterized so far (8, 15–19), five
of which are glycine substitutions. Except for one glycine sub-
stitution found in the NH2-terminal globular domain of the
COL6A3 (15), the missense mutations are all localized in the
triple helix of the three chains, and most likely exert a dominant-
negative effect (8, 16). The other three are splice-site mutations
in the COL6A1 gene, leading to a premature termination codon
(17) or a skipping of the same exon (18, 19). All three splicing
mutations affecting the COL6A1 gene cause haploinsufficiency.
These results demonstrate that both the dominant-negative
mutation and the haploinsufficiency cause BM.
We observed that UCMD shares some clinical features with
BM (4, 7, 10) but displays a more severe course. Therefore, we
investigated COL6 (12) in three unrelated patients with UCMD.
Here, we demonstrate that recessive mutations in the COL6A2
gene lead to UCMD. In addition, our results widen the clinical
spectrum of COL6 defects and disclose another pathogenetic
mechanism for CMD.
Materials and Methods
Patients and Their Families. Three Italian families were diagnosed
to be affected by Ullrich syndrome. Family A presented one
affected son, family B had two affected brothers, and family C
presented one daughter who had died at the age of 9 years and
one healthy sister. The parents in family A were consanguineous.
All parents were healthy and showed no clinical stigma.
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Peripheral Blood Samples, Muscle Biopsy, Skin Biopsy, and Fibroblast
Cell Culture. All of the biological material was collected after
obtaining appropriate informed consent. Peripheral blood sam-
ples were obtained from the members of all three families, and
genomic DNA was extracted (20). Muscle biopsy was obtained
from the proband of family C. Skin biopsies were obtained from
the probands of families A and B, and primary fibroblasts were
grown from the skin biopsies (16).
RNA Extraction and Reverse Transcription–PCR (RT-PCR). Total RNA
was extracted from fibroblasts by using the RNA fast kit (Biotecx
Laboratories, Houston) and treated with reverse transcriptase to
obtain a pool of cDNAs as described (21).
Heteroduplex Analysis and Direct Sequencing. Heteroduplex anal-
ysis of the PCR products corresponding to the triple-helical
domains of the three COL6 cDNAs was performed as reported
(16). After the first COL6A2 screening (15), the following set of
primers was used to amplify the entire COL6A2 cDNA and
obtain fragments between 253 and 466 nucleotides:
N-terminal globular domain—T1 (273 nt): 2N1s, GCACG-
GTGCTCACGCCTGT and 2N2as, ACCATGCAGTCCCC-
CACGGA; T2 (364 nt): 2N2s, GACTGCCCCATCCACGTG
and 2Ex3as1, CGTGGTCATCACCGACGG; and T3 (337 nt):
2Ex3s, GCAAGGGCACCGTCCACT and 2N1as, CCTCTG-
GCCCCAAGGG.
Triple helical domain—F9 (253 nt): 21s, GCTACCGTGGA-
CAGAAGGG and 24as, TCCCTTGCAGCCAGGAGGT; F10
(312 nt): 26s, AGGGCAAGCTGGGGCGCA and 2as, TGC-
CTGGGCTGCCCTTGG; F11 (294 nt): 22s, CCAAGGGCA-
GCCCAGGCA and 26as, CGCCTTTTTCTCCGGGTGC; and
F12 (258 nt): 27s, GTGATGCAGGACCCCGTG and 22as,
CTCGGGTCCTGGGACTCC.
C-terminal globular domain—F22 (466 nt): 2Ex22s, GGATC-
CTGGTCCCCCTGG and 2Ex26as, CGGTCGTAGGCAA-
ACTTGAG; F23 (404 nt): 2Ex26s, GAGCTTCAAGGAGGCT-
GTCA and 2Ex27as, TTTGGCAGGGAAGGTCTG.
The PCR was performed with denaturation at 96°C for 1 min,
an annealing temperature between 60°C and 64°C for 1 min and
an extension at 72°C for 1 min. PCR fragments displaying
heteroduplexes were submitted to direct sequencing, whereas for
the PCR fragments carrying deletionyinsertion, the alleles were
separated, eluted, reamplified, and sequenced as described (21).
Genomic DNA Analysis. Genomic DNA of the patients and their
relatives was amplified with the intronic oligonucleotides re-
ported below and the mutations were characterized through
heteroduplex analysis and direct sequencing. The C insertion in
the parents of family A was confirmed by amplifying a fragment
of 240 nts using the primers 2I12s (CCTTCCCCTGCCAAAA-
GACG) and 2I13as (CATGGCCCAGATGAACAGTC). The
amplified fragments underwent direct sequencing analysis. The
A3G single nucleotide substitution in intron 17 of family B was
detected by amplifying a fragment of 434 nucleotides with the
primers 2I17s (CTCAGAAGCCAGGACCTGCT) and 2I18as
(GCAGCTGCCTGAGGAGCAG). The presence of the muta-
tion was confirmed by digesting the genomic DNA of family B
and that of the parents of family C with DdeI. The A3 G single
nucleotide substitution in intron 23 was detected by amplifying
a fragment of 573 nucleotides with the primers 2I22s (TCTGC-
CCACGGTGGACCCA) and 2Ex25as (CTCCAGTGT-
GAAGTTGGTGTA).
Northern Blot Analysis. Total RNA samples (15 mg per lane) were
separated on a 1% agarose gel containing formaldehyde and
transferred to a Hybond N nylon membrane (Amersham Phar-
macia) following standard protocols (20). The membrane was
hybridized with a mixture of [32P]dCTP-labeled cDNA probes,
F157, F225, and FO19 (22, 23) which code for human a1(VI),
a2(VI), and a3(VI) collagen chains, respectively. Hybridization
and washing were performed under stringent conditions, and
signals were visualized by autoradiography.
Immunoprecipitation. Dermal fibroblasts were grown in DMEM
with 10% (volyvol) FBS in 35-mm dishes to confluence and then
incubated overnight in the same medium with 50 mgyml sodium
ascorbate. Cells were washed with PBS, incubated with serum-
free and methionine-free medium in the presence of 50 mgyml
sodium ascorbate for 2–3 h, which was then replaced with 1 ml
of fresh medium containing 100 mCiyml (1 Ci 5 37 GBq)
[35S]methionine (ICN) overnight. At the end of the labeling
period, 0.8 ml of medium was removed, and 0.2 ml of 53 lysis
buffer containing protease inhibitor (24) was added. Immuno-
precipitation with 1014 antibody specific for the a3(VI) collagen
chain (25) was performed as described (24).
Immunofluorescence of Cultured Fibroblasts. Fibroblast cultures
from the controls and from the patients were grown to conflu-
ence on coverslips and treated with 0.25 mM ascorbic acid for 5
days (26), washed in PBS, and fixed with cold methanol at 220°C
for 7 min. The slides were incubated for 1 h at room temperature
with a mouse monoclonal anti-COL6 antibody (MAB 3303;
Chemicon) and diluted 1:100 in PBS containing 2% (volyvol)
BSA and 5% (volyvol) normal goat serum. After several wash-
ings with 0.1% Tween-20yPBS, the slides were incubated with
secondary fluorescein-conjugated rabbit anti-mouse antibody
(Dako) and examined with a Nikon E600 f luorescence
microscope.
Immunofluorescence of Muscle Biopsies. Skeletal muscle biopsies
were trimmed and quickly frozen in methylbutane with liquid
nitrogen. Cryosections (7-mm thick) were air-dried for 1 h and
incubated at room temperature for 1 h with the following
primary antibodies: mouse monoclonal anti-CTVI, 2C6 anti-
body, against the light chain (140-kDa polypeptide) of COL6
(described by Hessle and Engvall diluted 1:5, ref. 26), and rat
monoclonal anti-merosin (Alexis Co., San Diego) diluted
1:1,000. Sections were washed in 0.1% Tween-20yPBS and then
incubated with anti-mouse and anti-rat biotinylated IgG (Am-
ersham Pharmacia), respectively, diluted 1:40 for 30 min. After
three washes in Tween-20yPBS, the binding reaction was de-
tected with streptavidin fluorescein (Amersham Pharmacia) at
1:250 dilution for 30 min. All antibody dilutions were made in
PBS (pH 7.4) containing 1% BSA (Sigma). Sections were
mounted in glycerolyPBS 1:1 and examined under a Zeiss
microscope equipped for epif luorescence.
Results
Clinical Studies on Patients and Their Families. In all three families,
the neurological examination, muscle testing, and creatine ki-
nase (CK) of parents were normal.
Family A. In family A, the parents, in their fifties and healthy,
were second-degree cousins. Their only son is (at the time of the
study) 11 years old. He was born at 41 weeks of gestation, had
an Apgar score of 6–10, and weighed 3.36 kg. Fetal movements
were reduced during pregnancy. At birth he was increased in
length (55 cm), showed multiple joint contractures of his knees
and elbows, a kyphotic contracture of the spine (Fig. 1B), a left
hip dislocation, bilateral congenital convex pes valgus, long and
slender fingers and toes with adducted thumbs, ogival palatus,
micrognatia, and a short neck with torticollis. He also showed
marked bilateral distal hyperlaxity of fingers (Fig. 1 A), toes,
calcanei, and wrists. At the age of 2 months, electromyography
of the deltoid muscle showed a myopathic pattern, whereas
motor and sensory nerve conduction velocity was normal for his
age. CK was increased 2-fold. Histology of the left quadriceps











muscle biopsy, performed at age 3 months, showed increased
diameter variability, rare sporadic necrotic fibers, and mild
endomisial fibrosis. The child walked at the age of 13 months, but
generalized muscle weakness persisted thereafter, and progres-
sive scoliosis and respiratory failure developed. He underwent
tracheostomy and nocturnal positive pressure mechanical ven-
tilation at the age of 8 years, with signs of diaphragmatic
insufficiency. The neurological examination at the age of 9 years
showed generalized muscle weakness which was particularly
severe in distal limb and neck flexor muscles [Medical Research
Council score (MRC) 5 3]; the other muscles tested had MRC 5
4. Torticollis and elbow contractures persisted. At the age of 11
years, he is still ambulant and has normal intelligence.
Family B. In family B, the proband is 3 years old at the time of
the study. He is the offspring of a first pregnancy and was born
at term. Both unrelated parents had a normal neurological
examination in their thirties, with normal electromyography and
normal CK values. Fetal movements were reported as normal,
weight was 3.1 kg at 41 weeks of gestation, length was 54 cm, and
occipital–frontal circumference was 36 cm. A younger brother
had neonatal hypotonia and delayed motor milestones, and
walked at 18 months with frequent falls. At birth, he was also
hypotonic, showed convergent strabismus, moderate kyphosis
with rigidity of the spine, ogival palate, and severe contractures
of elbows and knees. At the age of 8 months, he showed marked
distal hyperlaxity of toes, fingers, ankles, and wrists, and con-
tractures of both elbows and knees. His CK was 2- to 3-fold
higher. Electromyography showed a myopathic pattern, and
motor and sensory nerve conduction velocity was normal. His-
tology of the right quadriceps muscle bioposy performed at age
10 months showed increased diameter variability, rare isolated
necrotic fibers, and mild endomisial fibrosis. During the follow-
up, joint contractures slowly improved, and the child was able to
sit autonomously at age 1 year and walk at the age of 2 years.
Clinical examination at age 2 years confirmed distal hyperlaxity,
marked weakness of head flexors, and a kyphotic contracture of
the spine with an almost complete disappearance of limb joint
contractures.
Family C. In Family C, the parents, in their forties and healthy,
are both unrelated. The first daughter is healthy and aged 15
years at the time of the study. The proband was the product of
a second normal pregnancy and delivery. Her weight at birth was
2.9 kg, and in the neonatal period she was hypotonic with ogival
palate, slight micrognatia, kyphotic contracture of the spine, and
marked distal hyperlaxity of hands and feet with no joint
contractures. She had delayed motor milestones in the first 2
years of life and walked alone with difficulty at the age of 3 years.
Her CK was increased 2- to 3-fold. The girl was wheelchair-
bound by the age of 4 years, and severe scoliosis, associated with
signs of respiratory failure, appeared 1 year later. At age 6 years,
the neurological examination showed normal cognitive abilities,
generalized muscle wasting and weakness (MRC 5 3 in all distal
muscles and neck flexor muscles, and MRC 5 4 in biceps, triceps,
and quadriceps muscles), and elbow joint contractures. Facial
mimicry and swallowing was preserved. She had a tracheostomy
at age 7 years with positive pressure nocturnal mechanical
ventilation and was treated with a Harrington rod for severe
scoliosis at the age of 8 years. Histology of the paraspinal muscle
biopsy, performed during surgery for scoliosis, showed a striking
diameter variability, rare isolated necrotic fibers, and marked
endomisial fibrosis. One year later, the girl died of respiratory
failure with impairment of diaphragmatic movements.
Mutation Screening Analysis of COL6A1, COL6A2, and COL6A3 cDNAs.
We performed RT-PCR amplifications on RNA extracted from
fibroblasts of patients A and B or muscle of patient C (Fig. 2).
The overlapping PCR fragments, covering the COL6A1,
COL6A2, and COL6A3 cDNAs, underwent heteroduplex
analysis (16). Direct sequencing was carried out on all
heteroduplexes.
Family A. We first identified a homozygous insertion of a C in
a stretch of five Cs between nucleotides 1147 and 1151 of the
COL6A2 cDNA in the proband of family A, causing a slippage
of the reading frame with the formation of a premature termi-
nation codon at nucleotides 1347–1349 (Fig. 3A). The analysis of
the genomic DNA from the proband confirmed the presence of
a homozygous C insertion in exon 13 (27). Genomic DNA of
both apparently healthy parents showed that they carry the C
insertion. The mutation was not present in 50 unrelated controls.
The homozygous mutation is positioned in the area correspond-
ing to the amino-terminal one-third of the triple-helical domain
Fig. 1. Clinical aspect during the neonatal period of the patient in family A.
(A) A remarkable distal hyperlaxity of wrist and fingers. (B) A peculiar con-
genital kyphotic contracture of the spine in the baby.
Fig. 2. Pedigrees of UCMD families. Family A shows consanguinity between
the parents. Family B displays the presence of two affected sons and two
healthy parents formally demonstrating the presence of recessive mutations.
In family C, the proband carries a de novo mutation identical to one of family
B. The second mutation has not been found. We do not know which one of the
two parents carries a mutation.
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of the a2(VI) chain, leading to the complete absence of COL6
microfibrils, as shown by immunofluorescence of cultured fibro-
blasts (Fig. 4B).
Family B. In the proband of family B, we detected a heterozy-
gous 28-bp deletion in the COL6A2 cDNA between nucleotides
1459 and 1486. The deletion is caused by a single nucleotide
substitution, an A 3 G, at nucleotide 22 of intron 17 that
activates a cryptic acceptor splice site inside exon 18 (Fig. 3B).
The alternative splicing causes the loss of 9 aa and a frame shift
with the formation of a premature termination codon at nucle-
otides 1631–1633. Also, the younger affected brother and their
mother displayed the same mutation in the genomic DNA (data
not shown) that abolishes a DdeI restriction enzyme site. The
mutation was not found in 50 unrelated controls. We also
detected another mutation in the second allele of the same gene
in the C-terminal coding region; it was a deletion of 46 nucle-
otides covering the entire exon 24. The deletion in the cDNA is
caused by a single nucleotide substitution, a G 3 A at position
21 of intron 23 that causes the exon skipping (Fig. 3B). This
mutation is present in the two affected sons and in their father,
absent in the mother, and absent in 50 unrelated controls (data
not shown).
We also analyzed the expression of COL6 mRNA and protein
in fibroblasts from the proband of family B (Fig. 5). Hybridiza-
tion with cDNA probes for COL6A1, COL6A2, and COL6A3
simultaneously showed an almost total absence of COL6A2
mRNA, although a small amount of COL6A2 mRNA was
detected with a prolonged exposure of the autoradiogram (Fig.
5A). The low level of COL6A2 mRNA most likely results from
a premature termination codon-mediated mRNA degradation in
one allele and inefficiency in exon skipping in the other allele.
Immunoprecipitation of the fibroblast culture medium with
COL6 antibodies showed a marked reduction in the amount of
COL6 secreted into the medium (Fig. 5B). Presumably, the small
amount of COL6 secreted into the medium is composed of the
abnormal a2(VI) chains with the in-frame deletion at the C
terminus. Immunofluorescence showed the almost total absence
of COL6 in cultured fibroblasts (Fig. 4C). The muscle biopsy
showed the absence of immunolocalization of COL6 (Fig. 6B),
with normal expression of merosin (Fig. 6D)
Family C. The proband of family C showed the same 28-nt
deletion in exon 18 of COL6A2 as the first mutation detected in
family B and the same A 3 G substitution at nucleotide 22 of
intron 17 in the genomic DNA (data not shown). We did not find
the second mutation after direct sequencing of the entire
COL6A2 cDNA. We only have RNA and genomic DNA from a
muscle biopsy, i.e., no fibroblasts of the proband of family C are
available, because the patient died of respiratory failure at the
Fig. 3. Diagrammatic representation of mutations in families A, B, and C. (A)
The proband in family A has a homozygous insertion of a C in a stretch of Cs
between nucleotides 1147 and 1151 in exon 13 encoding the triple helix of
COL6A2. Both consanguineous parents are heterozygous for this mutation,
which causes a frame shift and the formation of a premature termination
codon at nucleotides 1347–1349 inside exon 16. (B) One of the COL6A2 alleles
in both affected sons of family B has an A3 G substitution at the conserved
splice acceptor site (ag) at position 22 in intron 17, causing the activation of
a cryptic acceptor site within exon 18. The aberrant splicing causes the deletion
of 28 bp (nucleotides 1459–1486 in exon 18 in the cDNA), the slippage of the
reading frame, and the formation of a premature termination codon at
nucleotides 1631–1633. Their apparently healthy mother and also the pro-
band in family C are heterozygous for the same mutation. (C) The second
COL6A2 allele of both affected sons in family B has a G 3 A substitution at
position 21 of intron 23, causing the skipping of the entire exon 24 of 46 bp
(from nucleotide 1671 to nucleotide 1716) and the changing of the reading
frame thereafter. Their apparently healthy father is heterozygous for this
mutation. The nucleotide positions are numbered according to the complete
coding sequence of the COL6A2 cDNA (GenBank accession no. AY029208)
with nucleotide 11 corresponding to the translation start site.
Fig. 4. Immunofluorescence of cultured fibroblasts in proposita of family A and B. (A) Immunofluorescence with anti-COL6 (see Materials and Methods) of
normal fibroblasts. COL6 is secreted in the extracellular matrix and seems organized in a dense three-dimensional network that is entangled with the cells. (B)
In fibroblasts of propositus of family A, COL6 is not detectable in the extracellular matrix, whereas a moderate labeling is present inside the cytoplasm of the
cells. (C) In the propositus of family B, COL6 is not detectable inside the cytoplasm of the cells whereas a residual labeling is present in the extracellular matrix
as small multiple dots. (Magnification 5 320).











age of 9 years. As with patient B, the muscle biopsy showed the
absence of immunolocalization of COL6 (Fig. 6F) with normal
expression of merosin (Fig. 6H). We obtained some genomic
DNA from peripheral blood lymphocytes of the two parents and
did not find the A 3 G substitution at nucleotide 22 of intron
17. Thus, the proband has a de novo mutation.
Discussion
We report four patients (three males and one female) affected
by UCMD showing clinical features of neonatal hypotonia,
multiple joint contractures at birth with a kyphotic rigidity of the
spine, and marked distal hyperlaxity of hands and feet. The
combination of joint contractures and distal hyperlaxity was
somewhat evocative of a collagen disorder and reminiscent of
milder clinical features already observed in patients with BM
(10). In addition, clinical evidence of autosomal recessive trans-
mission had already been reported in UCMD (5). Thus, we
decided to investigate the molecular defects, postulating reces-
sive mutations in the COL6 genes.
Altogether, our results indicate that homozygous or com-
pound heterozygous mutations in the COL6A2 gene (leading to
a severe impairment of COL6 deposition in the skeletal muscle)
cause UCMD. It is known that heterozygous mutations of the
COL6 genes cause BM, and these include missense mutations in
all three genes as well as mutations in COL6A1 that cause
haploinsufficiency (8, 15–19). It is, therefore, somewhat surpris-
ing that both parents in family A and the mother of family B, all
of whom carry heterozygous COL6A2 mutations leading to a
premature termination codon, are clinically healthy. It is note-
worthy that all of the three unrelated patients with Ullrich
recessive myopathy carry mutations in the COL6A2 gene,
whereas the haploinsufficiency of COL6 in BM patients reported
thus far is caused by mutations in the COL6A1 gene (17–19). A
possible explanation could be that the COL6A1 and COL6A2
genes are regulated differently. For instance, it is possible that
up-regulation of the normal COL6A2 allele could compensate
for the lack of expression of the abnormal COL6A2 allele,
whereas such a compensatory mechanism may not be operative
for the COL6A1 gene. In this context, we have shown that two
different promoters control the transcription of the COL6A2
gene (28), whereas only a single promoter has been found for the
COL6A1 gene (29). Alternatively, the recessive inheritance in
UCMD may be caused by the localization of the mutation, to the
kind of the mutation, and to the particular COL6 gene involved.
It is notable that, as with BM (8), we found the same mutation
in two unrelated UCMD patients. According to the results
obtained from family B, the proband of family C should also
carry another still-undetected mutation, probably in COL6A2.
Fig. 5. Analysis of COL6 mRNA and protein in fibroblasts from the proband
of family B. (A) Northern blot analysis showing little a2(VI) mRNA in the
patient’s fibroblasts. Fifteen mg of total RNA from fibroblasts of the proband
in family B (lane 1) and a control (lane 2) were run on a 1% denaturing agarose
gel, transferred to a nylon membrane, and hybridized with 32P-labeled cDNA
probes for the a1(VI), a2(VI), and a3(VI) collagen chains. The sizes of the a1(VI),
a2(VI), and a3(VI) collagen mRNAs are 4.2, 3.5, and 8–10 kb, respectively.
Multiple a3(VI) mRNAs result from alternative splicing of exons encoding the
N-globular domain (23). The amount of each splice variant varies in different
control fibroblast strains according to the growth state of cells. Therefore, the
difference in the intensity of the a3(VI) mRNA splice variants between the
control and the patient probably is not a direct consequence of the mutation.
(B) Immunoprecipitation showing a marked reduction in COL6 secretion.
Fibroblasts from a control (lane 1), the proband of family B (lane 2), and a
patient with BM (lane 3) were metabolically labeled overnight. The culture
media were immunoprecipitated with antibodies specific for the a3(VI) col-
lagen chain (25). The immunoprecipitated samples were reduced with 5%
2-mercaptoethanol and run on a 5% SDSypolyacrylamide gel. The a1(VI) and
a2(VI) collagen chains comigrated at 140 kDa, whereas the a3(VI) collagen
chains migrated at 260–300 kDa.
Fig. 6. Immunofluorescence of muscle in the proposita of family B (A–D) and
C (E–H). Immunolocalization of COL6–140 kDa (2C6 antibody; A, B, E, and F)
and merosin (C, D, G, and H) in skeletal muscle from controls (A, C, E, and G)
and patients (B, D, F, and H). The expression of COL6 was almost absent in
muscle fibers of the patient of family B (B), and drastically reduced in the
patient of family C (F), whereas merosin-staining seemed to be normal (D and
H). (Bar 5 80 mm.) These results show that this recessive disorder can be
screened by immunofluorescence using monoclonal antibodies directed
against one of the three COL6 subunits.
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Because we did not find any pathogenetic or nonpathogenetic
mutation by direct sequencing of the entire COL6A2 mRNA, it
is possible that the other mutation could affect mRNA degra-
dation or gene transcription, thereby leading to a complete
absence of COL6A2 mRNA. However, we cannot exclude a
genetic compound caused by mutations in the other two COL6
genes, COL6A1 and COL6A3.
In the follow-up, patients with UCMD characteristically
present respiratory failure with diaphragmatic paralysis; it is
noteworthy that the diaphragm was particularly involved in the
knockout animal model for COL6A1 (30). Moreover, it was also
demonstrated to be involved in BM patients (11). It should be
noted that the total absence of COL6A1 in mice leads to a mild
myopathy phenotype unlike the severe phenotype seen in Ullrich
patients with the absence of COL6A2.
Further investigation of the molecular defects in other UCMD
families and in other BM families will provide clues to the
genotype–phenotype correlation. Additional experiments will
also be required to analyze the effects of the mutations on the
protein structure and function. Our finding of an association
between UCMD and recessive mutations in the COL6A2 gene
opens up an important issue on the genetic characterization of
other CMD phenotypes with positive merosin, joint contrac-
tures, and distal hyperlaxity. Functional studies of the conse-
quences of gene mutations will help in better understanding
COL6 function and regulation.
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